Horizon Therapeutics Public Limited (NASDAQ:HZNP) Receives Consensus Rating of “Hold” from Brokerages

Shares of Horizon Therapeutics Public Limited (NASDAQ:HZNP – Get Rating) have been given a consensus recommendation of “Hold” by the fourteen research firms that are currently covering the stock, MarketBeat Ratings reports. Eight research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $111.00.

HZNP has been the topic of a number of research reports. TheStreet cut shares of Horizon Therapeutics Public from a “b-” rating to a “c+” rating in a research note on Monday, May 8th. StockNews.com initiated coverage on shares of Horizon Therapeutics Public in a research note on Sunday. They set a “buy” rating on the stock.

Horizon Therapeutics Public Stock Performance

Shares of NASDAQ:HZNP opened at $100.10 on Wednesday. The company’s 50 day simple moving average is $108.88 and its 200 day simple moving average is $105.71. The stock has a market capitalization of $22.88 billion, a price-to-earnings ratio of 62.96, a price-to-earnings-growth ratio of 2.99 and a beta of 1.13. The company has a debt-to-equity ratio of 0.50, a current ratio of 4.07 and a quick ratio of 3.89. Horizon Therapeutics Public has a 1 year low of $57.84 and a 1 year high of $113.83.

Horizon Therapeutics Public (NASDAQ:HZNP – Get Rating) last announced its quarterly earnings data on Wednesday, May 3rd. The biopharmaceutical company reported $0.83 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.17 by ($0.34). The firm had revenue of $832.10 million during the quarter, compared to the consensus estimate of $897.06 million. Horizon Therapeutics Public had a net margin of 10.40% and a return on equity of 20.31%. The business’s revenue was down 6.0% compared to the same quarter last year. During the same period last year, the business earned $1.34 earnings per share. As a group, research analysts predict that Horizon Therapeutics Public will post 4.81 EPS for the current fiscal year.

Institutional Trading of Horizon Therapeutics Public

Several institutional investors have recently modified their holdings of HZNP. Elequin Securities LLC acquired a new position in Horizon Therapeutics Public in the fourth quarter valued at $25,000. TFC Financial Management Inc. acquired a new position in Horizon Therapeutics Public in the first quarter valued at $25,000. Whittier Trust Co. of Nevada Inc. acquired a new position in Horizon Therapeutics Public in the fourth quarter valued at $28,000. CoreCap Advisors LLC acquired a new position in Horizon Therapeutics Public in the fourth quarter valued at $30,000. Finally, Ameritas Advisory Services LLC acquired a new position in Horizon Therapeutics Public in the first quarter valued at $31,000. Institutional investors own 91.01% of the company’s stock.

Horizon Therapeutics Public Company Profile

(Get Rating)

Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS.